(0.05%) 5 472.16 points
(0.09%) 39 149 points
(0.36%) 17 782 points
(0.01%) $80.84
(-3.66%) $2.66
(-0.80%) $2 312.10
(0.16%) $28.92
(3.51%) $1 021.00
(0.27%) $0.936
(0.69%) $10.68
(0.43%) $0.792
(-0.27%) $87.25
Live Chart Being Loaded With Signals
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States...
Stats | |
---|---|
今日成交量 | 162 881 |
平均成交量 | 1.21M |
市值 | 687.21M |
EPS | $-0.570 ( Q1 | 2024-05-06 ) |
下一个收益日期 | ( $-0.550 ) 2024-08-05 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-5.45 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0250 (0.19%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-27 | Kaye Edward M. Md | Buy | 159 000 | Employee Stock Option (Right to Buy) |
2024-03-27 | Kaye Edward M. Md | Buy | 105 000 | Restricted Stock Units |
2024-03-27 | Nash Huw M. | Buy | 60 000 | Employee Stock Option (Right to Buy) |
2024-03-27 | Nash Huw M. | Buy | 40 000 | Restricted Stock Units |
2024-03-27 | Ticho Barry | Buy | 60 000 | Employee Stock Option (Right to Buy) |
INSIDER POWER |
---|
-49.77 |
Last 98 transactions |
Buy: 1 784 499 | Sell: 5 127 514 |
音量 相关性
Stoke Therapeutics Inc 相关性 - 货币/商品
Stoke Therapeutics Inc 财务报表
Annual | 2023 |
营收: | $8.78M |
毛利润: | $4.05M (46.14 %) |
EPS: | $-2.38 |
FY | 2023 |
营收: | $8.78M |
毛利润: | $4.05M (46.14 %) |
EPS: | $-2.38 |
FY | 2022 |
营收: | $12.41M |
毛利润: | $8.87M (71.50 %) |
EPS: | $-2.39 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-2.33 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Stoke Therapeutics Inc
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。